ArticleJournal of abnormal psychology2017
Chronic cannabis use is associated with impaired fear extinction in humans.
Article in Journal of abnormal psychology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Evidence for pro-cognitive benefits of cannabinoids in people with bipolar disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial.Psychotherapy and psychosomatics · 2017Trial
- A process-oriented functional capacity assessment: First application of the neuropsychological evaluation of the UPSA (NEUPSA).Applied neuropsychology. Adult · 2026Article
- Chronic cannabis use in people with bipolar disorder is associated with comparable decision-making and functional outcome to healthy participants.Translational psychiatry · 2025Article
- Written Exposure Therapy for PTSD Integrated with Cognitive Behavioral Coping Skills for Cannabis Use Disorder After Recent Sexual Assault: A Case Series.Behavioral sciences (Basel, Switzerland) · 2025Article
- Impaired mnemonic pattern separation associated with PTSD symptoms paradoxically improves with regular cannabis use.Npj mental health research · 2025Article
- Endocannabinoid signaling in stress, nausea, and vomiting.Neurogastroenterology and motility · 2025Review
- Effects of Cannabis on PTSD Recovery: Review of the Literature and Clinical Insights.Current addiction reports · 2022Article
- Adolescent exposure to delta-9-tetrahydrocannabinol and ethanol heightens sensitivity to fear stimuli.Behavioural brain research · 2021Article
- Role of the stress response and the endocannabinoid system in ΔPsychopharmacology · 2020Article
- Reviewing the Potential of Psychedelics for the Treatment of PTSD.The international journal of neuropsychopharmacology · 2020Review
- Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms.Cannabis and cannabinoid research · 2020Review
- Sex differences in fear extinction.Neuroscience and biobehavioral reviews · 2019Review
- Rodent models of impaired fear extinction.Psychopharmacology · 2019Review
- Chronic substance use and self-harm in a primary health care setting.African journal of primary health care & family medicine · 2018Article
- Cannabis regulatory science: risk-benefit considerations for mental disorders.International review of psychiatry (Abingdon, England) · 2018Review
- Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Review
- Impact of Cannabis Use on Treatment Outcomes among Adults Receiving Cognitive-Behavioral Treatment for PTSD and Substance Use Disorders.Journal of clinical medicine · 2017Article
- Multimodal Correlates of Cannabis Use among U.S. Veterans with Bipolar Disorder: An Integrated Study of Clinical, Cognitive, and Functional Outcomes.Journal of dual diagnosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The use of fear conditioning and extinction paradigms to examine intermediate phenotypes of anxiety and stress-related disorders has facilitated the identification of neurobiological mechanisms that underlie specific components of abnormal psychological functioning. Across species, acute pharmacologic manipulation of the endogenous cannabinoid system has provided evidence of its critical role in fear extinction, but the effects of chronic cannabis on extinction are relatively understudied. In rats, chronic cannabinoid administration impairs fear extinction in a drug-free state. Here we examine whether chronic cannabis use is associated with impaired fear extinction in humans. Participants were healthy chronic cannabis users (n = 20) and nonuser controls with minimal lifetime cannabis use (n = 20) matched on age, sex, and race who all screened negative for psychiatric disorders. A 2-day differential fear conditioning paradigm was used to test the hypothesis that chronic cannabis use would be associated with impaired extinction of the skin conductance response. Consistent with hypotheses, chronic cannabis use was associated with reduced within-session extinction of skin conductance response on Day 1 (d = 0.78), and between-session extinction on Day 2 (d = 0.76). Unexpectedly, cannabis use was also associated with reduced subjective differentiation between threat and safety stimuli during conditioning. Replication and translation of findings are necessary to test potential mechanisms directly and examine whether impairments can be reversed pharmacologically or after a period of cannabis abstinence. (PsycINFO Database Record
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.